In recent times with modern approaches of systems biology we have expanded our understanding of microbial populations and their interactions with the human hosts. Even though the space is in its nascency, there are many companies developing new platforms and technologies for microbiome-based therapies, attracting millions of dollars in grants, awards and private equity financing. In the last month more than $270 million have been injected into the microbiome market.